logo
197,000 UK lives saved thanks to breast cancer advances

197,000 UK lives saved thanks to breast cancer advances

Yahoo12-03-2025

Almost 200,000 UK deaths from breast cancer have been averted since the late 80s, according to a new report.
Experts said that changes in how cancer is detected, diagnosed and treated have 'all been essential to these improvements'.
Overall, 1.5 million cancer deaths in the UK have been prevented since 1989, according to a new study predicting European cancer deaths in 2025.
But there will still be 173,300 cancer deaths overall in the UK this year, academics said.
Most cancer deaths among men in the UK in 2025 will be due to bowel; lung and prostate cancers.
While most cancer deaths among UK women will be due to bowel; lung and breast cancers.
Breast cancer deaths in the UK in 2025 will be lower than those observed in 2020 – with 11,400 women expected to die from breast cancer this year compared to 11,547 deaths in 2020.
The UK is also estimated to buck the trend when it comes to breast cancer deaths among elderly women – with deaths among over 80s attributed to breast cancer expected to rise in many European countries but fall in the UK.
Carlo La Vecchia, professor of medical statistics and epidemiology at the University of Milan in Italy, said: 'Elderly women are not covered by screening and probably are less favourably affected by the substantial advances in breast cancer management, including improvements in chemo and hormone therapy, but also in radiotherapy and surgery.
'The increased prevalence of overweight and obesity over the last few decades in most of northern and central Europe has led to an increased risk of breast cancer.
'In the elderly, this has not been counter-balanced by improved diagnosis and management. This accounts for the increased mortality in people aged 80 and over.'
In England, all women aged 50 to 71 are invited for breast cancer screening every three years.
Prof La Vecchia added: 'We estimate that between 1989 and 2025, 373,000 breast cancer deaths have been avoided in the EU and 197,000 in the UK.
'Most of these are due to improved management and therapy, but 25-30% are likely to be attributable to more widespread screening and early diagnosis.
'Given that breast cancer is now a largely curable cancer that requires modern integrated approaches, it is essential that all diagnoses of breast cancer are referred to comprehensive cancer centres, which can offer the complete range of therapies that might be required.
'As indicated by the unfavourable trends in elderly women, control of overweight and obesity is a priority now, not only for cardiovascular diseases, but also for cancer, including breast cancer.'
Commenting, Jon Shelton, Cancer Research UK's head of cancer intelligence, said: 'Breast cancer mortality rates have fallen substantially in the UK since the early 1970s, and it's extremely positive to see that trend continue.
'Breakthroughs in how we detect, diagnose and treat the disease have all been essential to these improvements.
'Studies like this showcase the power of science, and if the UK Government's upcoming national cancer plan for England prioritises reform and investment in cancer services and getting research and innovation into care, we'll see even more improvements for people affected by cancer.'
Dr Kotryna Temcinaite, head of research communications and engagement at Breast Cancer Now, said: 'It's reassuring that this research suggests that nearly 197,000 deaths from breast cancer have been avoided in the UK in the last 37 years across women of all ages.
'This could be due to a combination of increased awareness and improvements in cancer detection and treatment. But the stark reality is that 11,500 women still die from this devastating disease each year in the UK, making research into how we better diagnose and treat breast cancer more needed than ever.
'Most breast cancers (80%) occur in women aged over 50, and a quarter (25%) of cases are diagnosed in women aged 75 and over.
'It's crucial that all women regularly check their breasts and get to know their 'normal'.'
Dame Cally Palmer, national cancer director at NHS England, said: 'It's incredibly encouraging that deaths from breast cancer in the UK are continuing to fall as a result of improved early diagnosis and treatment.
'We know a third of women don't take up their invites for the scans which can detect cancer earlier, when treatment has the best chance of success – so I'd urge anyone who receives an invite to book a potentially life-saving appointment for NHS breast cancer screening.'
The new review, by a team of international researchers, also predicts small reductions in lung cancer deaths for both men and women in the UK.
But bowel cancer deaths are expected to increase from the absolute numbers in 2020, according to the new study, which has been published in the journal Annals of Oncology.
Pancreatic cancer deaths are also expected to rise, according to the estimates.
Prof La Vecchia said: 'Trends in cancer mortality continue to be favourable across Europe, however, there are a few negative indications – these include deaths from bowel cancer in people younger than 50, which have started to increase in the UK and several central and northern Europe countries, mainly due to increased prevalence of overweight and obesity in the young who are not covered by colorectal cancer screening.
'In addition, death rates from pancreatic cancer are not decreasing in the EU, and it is now the fourth cause of cancer death in Europe after lung, colorectal and breast cancer.
'Death rates from lung cancer are starting to level off but not yet to decrease in EU women. The trends in pancreatic and female lung cancer underline the urgency of implementing stricter tobacco control across Europe.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress
Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

Yahoo

timean hour ago

  • Yahoo

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders. The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance. Biovica's financial targets: FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million FY 2025/26: Net sales of SEK 50 million FY 2026/27: Net sales of SEK 150 million With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27. The expected distribution of revenues during FY25/26 and FY 26/27 are: 65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships 30% from pharma services, based on ongoing and future biomarker collaborations 5% from European partners, through distributor and lab agreements across 18 territories "These targets reflect the solid groundwork we have laid over the past years," says Anders Rylander, CEO of Biovica. "We've achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up. The pieces are in place to deliver on our vision-improving outcomes for patients, optimizing care for providers, and generating long-term value for shareholders." Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-10 18:31 CEST. Attachments Biovica announces financial targets following key partnerships and commercial progress SOURCE: Biovica International View the original press release on ACCESS Newswire

‘Boil in the bag' funerals could be introduced in UK after European roll-out in Ireland
‘Boil in the bag' funerals could be introduced in UK after European roll-out in Ireland

Yahoo

time3 hours ago

  • Yahoo

‘Boil in the bag' funerals could be introduced in UK after European roll-out in Ireland

"Boil in a bag" funerals - already used widely in America - could soon be made available across the UK. This environmentally friendly, yet controversial, way to say your final goodbyes to a loved one has already been rolled out in Ireland back in 2023 and could come to the UK next. This unusual method, officially known as water cremation or alkaline hydrolysis, is currently effectively banned in the UK, but could well get the legal go-ahead following the independent Law Commission's new consultation into funerary methods. READ MORE: Dad, 32, who flew to Turkey for family holiday dies hours after being escorted off plane READ MORE: Met Office verdict on UK heatwave this WEEK as temperatures to climb to 29C Already available across 30 US states, as well as Canada and South Africa, the first European water cremation facility, or resomation, opened its doors in early 2023 in Navan, Co Meath, Ireland. Traditional burials can lead to embalming fluid seeping into the grave soil, while each gas-powered fire cremation releases around 245kg of CO2 into the atmosphere, according to UK-based cemetery and crematorium development the CDS Group. By comparison, figures from Resomation Ltd, the founding body for alkaline hydrolysis, show just 28kg of CO2 is released into the atmosphere per water cremation. Unlike conventional cremations, these eco-friendly farewells, which take between three to four hours, also don't release harmful mercury emissions into the atmosphere. But you might be wondering how the process actually works. Well, first the body is loaded into the alkaline hydrolysis machine, which calculates the amount of water and potassium hydroxide required. The machine locks and an alkaline solution fills the pressurised tank, which is gently heated to 152C. The remains get broken into their chemical components - amino acids, peptides, sugars and salt - leaving behind a liquid that is then cooled in another tank until sterile and free from any remaining tissue or DNA. Around 330 gallons of brown-coloured liquid will be washed down the drain, while the softened bones are ground to powder in a reducer, and presented in an urn to the grieving family. In 2017, Wired journalist Hayley Campbell described the process in colourful detail after seeing a resomator in action at the University of California, Los Angeles (UCLA). Hayley wrote: "Over the course of up to four hours, the strong alkaline base causes everything but the skeleton to break down to the original components that built it: sugar, salt, peptides and amino acids; DNA unzips into its nucleobases, cytosine, guanine, adenine, thymine. "The body becomes fertiliser and soap, a sterile watery liquid that looks like weak tea. The liquid shoots through a pipe into a holding tank in the opposite corner of the room, where it will cool down, be brought down to an acceptable pH for the water treatment plant, and be released down the drain." Noting that "it's not actually that terrible", Hayley revealed: "The human body, liquefied, smells like steamed clams." Highlighting why this process is still a bit of a taboo in an interview with The Telegraph, Dr Lian Lundy, a wastewater specialist from Middlesex University, explained: "Some people view it as basically mixing up my loved one with poo in the sewer and they don't like that. "But there's a lot that goes into the sewer that we don't really think about – waste from mortuaries and hospitals and all sorts of things that we don't know about – so from that perspective, it's not really any different."

Navigate EU Clinical Trial Regulations with Confidence: Virtual Seminar on EU Clinical Trial Regulation - EU Filings & Registrations
Navigate EU Clinical Trial Regulations with Confidence: Virtual Seminar on EU Clinical Trial Regulation - EU Filings & Registrations

Yahoo

time5 hours ago

  • Yahoo

Navigate EU Clinical Trial Regulations with Confidence: Virtual Seminar on EU Clinical Trial Regulation - EU Filings & Registrations

This comprehensive course on EU Clinical Studies covers the EU Clinical Trial Regulation, EU-GCP updates, and new Pharmacovigilance Directive insights. Attendees will learn about EU regulatory frameworks, licensing methods, and effective submission strategies. The seminar includes Q&A, handouts, and certificates. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Virtual Seminar on The EU Clinical Trial Regulation - EU Filings & Registration (August 20, 2025)" has been added to offering. This course covers the requirements for conducting Clinical Studies across the EU via the requirements of the EU Clinical Trial Regulation (for Drugs & Biologics). The course also covers recent updates on EU-GCP associated with the new regulatory framework and highlights the new EU Pharmacovigilance Directive, as it relates to studies and helpful tips for working with European regulators. The seminar covers the impending changes coming with the EU Parliament's passage of the EU Clinical Trial Regulation, which will affect all trials conducted across the EU [new and ongoing]. This course also covers the various licensing methods (for Drugs, Biologics & Combination Products) by which applicants can file for product licenses (Marketing Authorizations) in one or multiple Member States [and EEA], as well as fully across all Member States of the European Union. This course specifically outlines and discusses the structure of the regulatory agencies at the EU level and across the specific Member States. Course content will explain which procedures are available for which products and then will follow the license processing steps for each pathway. Learning Objectives Attendees will leave the Course clearly understanding the requirements under the current Regulations. In addition, this course has been updated to provide participants with competitive insight into: How the EU and individual countries within Europe Interact Which registration procedure to use How regulations affect product development strategies Understanding the concerns/issues of European Regulatory Personnel How to negotiate with the regulators Information necessary for effective submissions Strategies for streamlining the registration application process for faster approval The advantages and disadvantages of various registration procedures How to efficiently initiate trials first patient, first visit How to link the strategy of Country Selection to an ultimate EU registration pathway How to stay compliant What can make the difference in your data passing Regulatory scrutiny Related area-GCP and PV-reporting updates Impending Changes of the EU Clinical Trial Regulation and timing for Implementation This live training Seminar includes the following for each registered attendee: A copy of the presentation slides by download A certificate of participation for attendee training records Q/A Session Free Handouts on EU Clinical Trial Regulation Who Should Attend: Business Management Project Team Members Legal Team Members Clinical Operations Staff Quality Assurance, Monitors, CRAs Regulatory Affairs Investigators & Site Study Staff CROs, Consultants, Insurers Course Agenda: Session 1: EU's New Regulation 535/2014 on Clinical Trials, 2022 (77 slides) Introduction - Foundation of Science-based Clinical Trials Clinical Trial Basics EU Regulation 536/2014, recently implemented Trial subjects' concerns / rights Session 2: ICH Q7, API CGMPs and QMS (81 slides) ICH Q7 API CGMP Additional CGMP considerations Required Records Methods Validation Session 3: Risk Management in EU New Drug Development (53 slides) ICH Q9 Risk Management File - Narrative Hazards List, FTA, D-, P-, U-FME[C]A's Review / Report; Use Session 4: Investigational Medicinal Products (IMPs) (22 slides) EU Medicinal Products Requirements IMPs Session 5: EU Clinical Trials Application Process (36 slides) Application Process AMS, CMS Required documents. Review Q & A For more information about this webinar visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store